KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study

被引：6
|
作者：
Bassetti, Matteo [1 ,2 ]
Carannante, Novella [3 ]
Pallotto, Carlo [3 ,4 ]
Righi, Elda [1 ,2 ]
Di Caprio, Giovanni [5 ]
Bernardo, Mariano [6 ]
Sodano, Giuseppe [6 ]
Mallardo, Enza [6 ]
Francisci, Daniela [4 ]
Sartor, Assunta [1 ,2 ]
Graziano, Elena [1 ,2 ]
Tascini, Carlo [3 ]
机构：
[1] Univ Udine, Dept Med, Infect Dis Div, Piazzale Santa Maria Misericordia 15, Udine, Italy
[2] Santa Maria Misericordia Univ Hosp, Piazzale Santa Maria Misericordia 15, Udine, Italy
[3] AORN Colli, Cotugno Hosp, Div Infect Dis 1, Via G Quagliariello 51, I-80131 Naples, Italy
[4] Univ Perugia, Dept Med, Infect Dis Sect, Piazzale Gambuli 1, Perugia, Italy
[5] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Publ Med, Infect Dis Sect, Naples, Italy
[6] AORN Colli, Cotugno Hosp, Microbiol & Virol Unit, Via G Quagliariello 51, Naples, Italy
来源：
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE | 2019年 / 17卷
关键词：
Carbapenemase-producing Klebsiella pneumoniae; KPC; Ceftazidime/avibactam; Ceftazidime; Gut decolonisation; ORAL GENTAMICIN; RESISTANT; DECONTAMINATION; INFECTIONS; COLONIZATION; ERADICATION;
D O I：
10.1016/j.jgar.2018.11.014
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Objectives: KPC-producing Klebsiella pneumoniae (KPC-Kp) gut colonisation is a major risk factor for developing systemic infection. Ceftazidime/avibactam (CAZ/AVI) may have a role as decolonisation therapy in special situations. Methods: This was a retrospective, observational, multicentre study. The KPC-Kp gut decolonisation rate of CAZ/AVI-based therapy (Group A) was compared with other antimicrobial regimens (Group B) in patients with KPC-Kp infection. Results: Among 12 patients in Group A, 11 (91.7%) achieved gut decolonisation. None of the 24 patients of Group B were decolonised. Conclusion: CAZ/AVI-based therapy could be useful in KPC-Kp gut decolonisation in high-risk patients. (C) 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：109 / 111
页数：3
相关论文
共 50 条
  • [21] In vitro activity of ceftazidime/avibactam against KPC-producing Klebsiella pneumoniae in Greece: A single-centre study
    Protonotariou, Efthymia
    Meletis, Georgios
    Kachrimanidou, Melania
    Papadopoulou, Dimitra
    Stamou, Aikaterini
    Arhonti, Maria
    Skoura, Lemonia
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 20 : 82 - 83
  • [22] Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae
    Zheng, Mei
    Li, Fu-Hao
    Liu, Juan
    Li, Wen-Jie
    Yin, Ruo-Xi
    Cai, Da-Tong
    Andrey, Diego O.
    Zheng, Si-Lin
    Gales, Ana C.
    Zhang, Wan-Jiang
    Sun, Jian
    Liao, Xiao-Ping
    Yu, Yang
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (05) : 1069 - 1080
  • [23] Changes in KPC-producing Klebsiella pneumoniae susceptibility from the pre- to ceftazidime-avibactam era
    Boattini, Matteo
    Bianco, Gabriele
    Comini, Sara
    Iannaccone, Marco
    Casale, Roberto
    Charrier, Lorena
    Cavallo, Rossana
    Costa, Cristina
    INFECTIOUS DISEASES, 2022, 54 (04) : 311 - 313
  • [24] Pharmacokinetics of Ceftazidime-Avibactam in Two Patients With KPC-Producing Klebsiella pneumoniae Bacteremia and Renal Impairment
    Veillette, John J.
    Truong, James
    Forland, Steven C.
    PHARMACOTHERAPY, 2016, 36 (11): : E172 - E177
  • [25] Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization
    Gaibani, P.
    Re, M. C.
    Campoli, C.
    Viale, P. L.
    Ambretti, S.
    CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (04) : 516.e1 - 516.e4
  • [26] Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series
    van Asten, S. A., V
    Boattini, M.
    Kraakman, M. E. M.
    Bianco, G.
    Iannaccone, M.
    Costa, C.
    Cavallo, R.
    Bernards, A. T.
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2021, 27 (05) : 778 - 780
  • [27] Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018–2022)
    Matteo Boattini
    Gabriele Bianco
    Paulo Bastos
    Sara Comini
    Silvia Corcione
    André Almeida
    Cristina Costa
    Francesco Giuseppe De Rosa
    Rossana Cavallo
    European Journal of Clinical Microbiology & Infectious Diseases, 2024, 43 : 155 - 166
  • [28] In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing Klebsiella pneumoniae Clinical Isolates
    Palombo, Marta
    Secci, Benedetta
    Bovo, Federica
    Gatti, Milo
    Ambretti, Simone
    Gaibani, Paolo
    ANTIBIOTICS-BASEL, 2023, 12 (12):
  • [29] Ceftazidine-avibactam salvage therapy in newborn with KPC-producing Klebsiella pneumoniae invasive infections
    Esposito, Pasquale
    Sbrana, Francesco
    Di Toro, Antonino
    Gombos, Sara
    Tascini, Carlos
    MINERVA ANESTESIOLOGICA, 2019, 85 (07) : 804 - 805
  • [30] Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study
    Oliva, A.
    Volpicelli, L.
    Di Bari, S.
    Curtolo, A.
    Borrazzo, C.
    Dezza, F. Cogliati
    Cona, A.
    Agrenzano, S.
    Mularoni, A.
    Trancassini, M.
    Mengoni, F.
    Stefani, S.
    Raponi, G.
    Venditti, M.
    JAC-ANTIMICROBIAL RESISTANCE, 2022, 4 (06):
12345